LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.40 In stock
5 mg $218.70 In stock
10 mg $337.40 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • Z5645

    Zoledronate Disodium Tetrahydrate

    Bisphosphonate; FPPS inhibitor.

    ≥98%
  • C5592

    CNX-774

    BTK inhibitor.

    ≥98%
  • M704789

    MRTX1133

    KRAS inhibitor

    ≥98%
  • T1016

    Propyl Analog of Paclitaxel

    Fermentation impurity

    ≥95%
  • F4679

    Flubendazole

    Benzimidazole; microtubule polymerization inhib...

    ≥98%
  • M3379

    Mitoxantrone Dihydrochloride

    Anthracenedione, DNA intercalator; Pim-1 inhibi...

    ≥98%
  • T2934

    Thiamphenicol Palmitate

    Chloramphenicol derivative; protein translation...

    ≥98%
  • C1613

    Cediranib

    VEGFR inhibitor.

    ≥98%
  • I0933

    Icilin

    TRPM8 activator, TRPV3 blocker.

    ≥98%
  • H9712

    (E)-4-Hydroxytamoxifen

    SERM.

    ≥97%
  • P1854

    Penicillic Acid

    Neuroactive mycotoxin produced by Penicillum an...

    ≥98%
  • T0153

    Tanshinone I

    Diterpene found in Salvia.

    ≥95%
  • T2668

    TGR5 Receptor Agonist

    TGR5 agonist.

    ≥99%
  • T2933

    4-Thiouridine

    Modified nucleotide used for labeling DNA; DNA ...

    ≥99%
  • B8676

    BVT-2733

    11β-HSD1 inhibitor.

    ≥98%
  • P6854

    Progesterone

    Endogenous steroid hormone involved in reproduc...

    ≥98%
  • C9879

    Cytochalasin B

    Mycotoxin produced by Aspergillus; actin polyme...

    ≥98%
  • B5753

    Bongkrekic Acid

    Respiratory toxin, mitochondrial permeability t...

    ≥95%
  • A7204

    AS-605240

    p110δ PI3K inhibitor.

    ≥98%
  • A4849

    Amyloid-β (25-35)

    Endogenous APP peptide cleavage product, primar...

    ≥95%